Gerestein CG - Search Results

1

Prediction of residual disease after primary cytoreductive surgery for advanced-stage ovarian cancer: accuracy of clinical judgment.

Gerestein CG, van der Spek DW, Eijkemans MJ, Bakker J, Kooi GS, Burger CW. Gerestein CG, et al. Int J Gynecol Cancer. 2009 Dec;19(9):1511-5. doi: 10.1111/IGC.0b013e3181bf82be. Int J Gynecol Cancer. 2009. PMID: 19955927 Clinical Trial.

2

Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.

de Jong D, Eijkemans MJ, Lie Fong S, Gerestein CG, Kooi GS, Baalbergen A, van der Burg ME, Burger CW, Ansink AC. de Jong D, et al. Among authors: gerestein cg. Oncology. 2007;72(5-6):293-301. doi: 10.1159/000113051. Epub 2008 Jan 14. Oncology. 2007. PMID: 18198490

3

The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma.

Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC. Gerestein CG, et al. BJOG. 2009 Feb;116(3):372-80. doi: 10.1111/j.1471-0528.2008.02033.x. BJOG. 2009. PMID: 19187369

4

Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review.

Gerestein CG, Damhuis RA, Burger CW, Kooi GS. Gerestein CG, et al. Gynecol Oncol. 2009 Sep;114(3):523-7. doi: 10.1016/j.ygyno.2009.03.011. Epub 2009 Apr 2. Gynecol Oncol. 2009. PMID: 19344936 Review.

5

Causes of postoperative mortality after surgery for ovarian cancer.

Gerestein CG, Damhuis RA, de Vries M, Reedijk A, Burger CW, Kooi GS. Gerestein CG, et al. Eur J Cancer. 2009 Nov;45(16):2799-803. doi: 10.1016/j.ejca.2009.06.004. Epub 2009 Jul 15. Eur J Cancer. 2009. PMID: 19615887

6

Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer.

Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Gerestein CG, et al. Eur J Cancer. 2010 Jan;46(1):102-9. doi: 10.1016/j.ejca.2009.10.017. Eur J Cancer. 2010. PMID: 19900801

7

Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.

Gerestein CG, Eijkemans MJ, Bakker J, Elgersma OE, van der Burg ME, Kooi GS, Burger CW. Gerestein CG, et al. Anticancer Res. 2011 Nov;31(11):4043-9. Anticancer Res. 2011. PMID: 22110240

8

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer.

van de Laar R, IntHout J, Van Gorp T, Verdonschot S, van Altena AM, Gerestein CG, Massuger LF, Zusterzeel PL, Kruitwagen RF. van de Laar R, et al. Among authors: gerestein cg. Br J Cancer. 2014 Jan 7;110(1):42-8. doi: 10.1038/bjc.2013.717. Epub 2013 Nov 19. Br J Cancer. 2014. PMID: 24253502 Free PMC article.

9

Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer.

Nieuwenhuyzen-de Boer GM, Gerestein CG, Eijkemans MJ, Burger CW, Kooi GS. Nieuwenhuyzen-de Boer GM, et al. Among authors: gerestein cg. Eur J Gynaecol Oncol. 2016;37(1):63-8. Eur J Gynaecol Oncol. 2016. PMID: 27048112

10

Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.

Timmermans M, Sonke GS, Slangen BFM, Baalbergen A, Bekkers RLM, Fons G, Gerestein CG, Kruse AJ, Roes EM, Zusterzeel PLM, Van de Vijver KK, Kruitwagen RFPM, van der Aa MA. Timmermans M, et al. Among authors: gerestein cg. Eur J Surg Oncol. 2019 Aug;45(8):1425-1431. doi: 10.1016/j.ejso.2019.04.009. Epub 2019 Apr 12. Eur J Surg Oncol. 2019. PMID: 31027945

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters